Nanatinostat + Valganciclovir/Pembrolizumab for Nasopharyngeal Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a combination of nanatinostat, valganciclovir, and pembrolizumab in patients with certain EBV-related cancers. Nanatinostat makes cancer cells more vulnerable, allowing valganciclovir to kill them, while pembrolizumab boosts the immune system to fight the cancer.
Research Team
Darrel P Cohen, MD, PhD
Principal Investigator
Viracta Therapeutics
Eligibility Criteria
This trial is for adults with advanced EBV+ solid tumors, including nasopharyngeal carcinoma, who've tried at least one platinum-based chemotherapy but no more than three treatments. They must have measurable disease and be in good physical condition (ECOG 0 or 1), with proper bone marrow and liver function.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1b Dose Escalation
Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, and valganciclovir starting at 900 mg orally daily to evaluate safety and determine the recommended Phase 2 dose
Phase 1b Cohort
Patients with other EBV+ solid tumors receive nanatinostat in combination with valganciclovir at the RP2D
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Nanatinostat
- Pembrolizumab
- Valganciclovir
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viracta Therapeutics, Inc.
Lead Sponsor